Dr. Lal PathLabs announced its Q2 FY27 results, showcasing robust financial performance with a 19.6% year-on-year revenue growth to ₹874 crore. The company also reported a significant increase in EBITDA by 25.1% to ₹280 crore and a 27.5% jump in PAT to ₹194 crore. The transcript highlights strategic initiatives like the acquisition of S N GeneLab and international expansion, alongside guidance for the full year.
Dr. Lal PathLabs Announces Strong Q2 FY27 Results
Dr. Lal PathLabs Limited has disclosed its financial results for the second quarter and first half of the financial year 2027. The company demonstrated a strong growth trajectory, with revenue for Q2 FY27 reaching ₹874 crore, an increase of 19.6% compared to ₹731 crore in the same quarter last year. For the first half of FY27, revenue stood at ₹1,672 crore, marking a growth of 19.4%.
Key Financial Highlights
The company’s operational performance was robust, with EBITDA for Q2 FY27 growing by 25.1% to ₹280 crore, resulting in an EBITDA margin of 32.1%. For the first half of FY27, EBITDA was ₹528 crore, a 26.7% increase from H1 FY26. Profit After Tax (PAT) for Q2 FY27 saw a substantial rise of 27.5% to ₹194 crore, with a PAT margin of 22.2%. The first half PAT grew by 27.3% to ₹364 crore.
Strategic Initiatives and Outlook
The management highlighted key strategic pillars, including scientific leadership, enhanced patient experience, and operational excellence. Recent initiatives include the acquisition of S N GeneLab to strengthen its genomics portfolio and expansion into international markets with acquisitions in Ghana and a JV in Uzbekistan. The company is also focusing on expanding its rural outreach program. Management expressed confidence in sustaining growth momentum, with revenue guidance for the full year expected to be in the high teens, similar to the EBITDA guidance.
Investor Information
The company announced an interim dividend of 50% (₹5 per share). Net cash as of September 30, 2026, stood at ₹1,746 crore. Working capital management remains efficient with negative net working capital at 16 days.
Source: BSE
